摘要
目的:分析GDP治疗难治复发弥漫大B细胞淋巴瘤的近期疗效和毒副反应。方法:22例使用过CHOP或CHOP样方案的难治/复发DLBCL患者,给予Gem1 g/m2,d1、d8;DXM 10 mg/m2,d1～d4;DDP 25 mg/m2,静脉滴入,d1～d3;21 d为1个周期。结果:患者分别进行了2～6个周期的GDP方案解救治疗,CR 18.18%,PR 36.36%,总有效率54.54%。GCB与Non-GCP组、复发组与未缓解组、有骨髓侵犯与无骨髓侵犯组、LDH正常组与LDH升高组之间缓解率均无差别(P值分别为0.639、0.361、0.594和0.639)。白细胞下降15例(Ⅲ度5例,占23%,Ⅳ度0例),血小板下降6例(27.27%),均为Ⅰ～Ⅱ度,血红蛋白下降6例(27.27%),为轻度,不需输注红细胞;恶心、呕吐7例(31.82%)。未出现Ⅲ～Ⅳ度心脏和肾脏毒性,无化疗相关性死亡。结论:GDP治疗复发难治弥漫大B细胞非霍奇金淋巴瘤有较好的近期疗效,且患者耐受性好,骨髓毒性较轻,尤其对于拟进行干细胞移植的患者,是值得推荐的一个挽救方案。
OBJECTIVE： To determine the response rate and toxicity of gemcitabine,dexamethasone,and cisplatin for recurrent or refractory diffuse large B cell non-Hodgkin＇s lymphoma.METHODS： Twenty-two patients with recurrent or refractory diffuse large B-cell NHL,measurable disease,receiving one previous chemotherapy regimen were eligible.The treatment consisted of gemcitabine 1 000 mg/m^2 intravenously on days 1 and 8,dexamethasone 10 mg/m^2 i.v on days 1-4,and cisplatin 25 mg/m^2 i.v on days 1-3,every 21 days.RESULTS： There were 4 complete responses（CR18.18%） and 8 partial responses（PR36.36%）.The overall response rate（RR） was 54.54%.There were no differences between the GCB group and non-GCB group,recurrence group and never response group,bone marrow invasive group and non bone marrow invasive group in the response rates.（P values were 0.639,0.361,0.594,0.639 respectively）.Grade 3 neutropenia occurred in 23% of patients,while,no grade 4.Grade 1 and 2 thrombocytopenia occurred in 27.27% of patients totally.There was no grade 3 and 4 thrombocytopenia occurred.Grade 1 and 2 anemia occurred in 27.27% of patients.Nausea and vomiting cases（31.82%）.No severe cardiac and kidney toxicities were observed and there was no treatment related death.CONCLUSION： GDP is an active regimen in recurrent or refractory diffuse large B cell non Hodgkin＇s lymphoma with an acceptabe toxicity.
出处
《中华肿瘤防治杂志》
CAS
2010年第6期452-454,共3页
Chinese Journal of Cancer Prevention and Treatment
关键词
非霍奇金淋巴瘤/药物疗法
有效率
毒副反应
GDP
Diffuse large B cell non-Hodgkin＇s lymphoam/drug therapy
response rate
toxicity
GDP
